Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.

Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.
复制标题

DOI:
10.3389/fonc.2022.925818
复制
发表时间:
2022
影响因子:
4.7
通讯作者:
Mark, Tomer M.
Mark, Tomer M.
中科院分区:
医学3区
文献类型:
--
作者:
Keller, Alana L.;Sherbenou, Daniel W.;Forsberg, Peter A.;Mark, Tomer M.

文献摘要

参考文献

相似文献

多发性骨髓瘤是一种无法治愈的血液系统恶性肿瘤。骨髓瘤患者的典型病程特征是最初的治疗反应,然后是最终的耐药性发展。只要患者有新的治疗方法,随后的缓解和复发周期就会继续进行。这一现实促使了许多新型免疫疗法的发展。这些药物中的许多都利用了患者自身T细胞的细胞毒能力,有效地将它们重新定向到骨髓瘤细胞,否则这些细胞正在逃避免疫攻击。包括CAR T细胞治疗和双特异性抗体在内的方法在骨髓瘤患者的临床试验中显示出令人印象深刻的疗效。这篇综述考察了在多发性骨髓瘤治疗中利用T细胞的不同方法,并调查了这些令人兴奋的新策略的好处和风险。
Multiple myeloma is an incurable hematologic malignancy. The typical disease course for myeloma patients is characterized by initial response to treatment followed by eventual development of resistance. Subsequent cycles of remission and relapse proceed as long as patients have new lines of therapy available to them. This reality has prompted development of many novel immunotherapeutics. Many of these drugs exploit the cytotoxic capabilities of the patients’ own T cells, effectively redirecting them to myeloma cells that are otherwise evading immune attack. Approaches including CAR T cell therapy and bispecific antibodies have displayed impressive efficacy in clinical trials for myeloma patients. This review examines the different approaches that utilize T cells in multiple myeloma therapy and investigates the benefits and risks of these exciting new strategies.
DOI: 10.1182/blood-2017-03-775122
发表时间: 2017-09-07
期刊: BLOOD
影响因子: 20.3
作者:
Badros, Ashraf;Hyjek, Elizabeth;Singh, Zeba
通讯作者: Singh, Zeba
DOI: 10.1038/s41596-019-0170-6
发表时间: 2019-06-01
期刊: NATURE PROTOCOLS
影响因子: 14.8
作者:
Ali, Muhammad;Foldvari, Zsofia;Olweus, Johanna
通讯作者: Olweus, Johanna
DOI: 10.1158/1078-0432.ccr-20-3770
发表时间: 2021-10-15
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者:
通讯作者: --
DOI: 10.1001/jamaoncol.2018.2128
发表时间: 2018-09-01
期刊: JAMA oncology
影响因子: 28.4
作者:
Cowan AJ;Allen C;Barac A;Basaleem H;Bensenor I;Curado MP;Foreman K;Gupta R;Harvey J;Hosgood HD;Jakovljevic M;Khader Y;Linn S;Lad D;Mantovani L;Nong VM;Mokdad A;Naghavi M;Postma M;Roshandel G;Shackelford K;Sisay M;Nguyen CT;Tran TT;Xuan BT;Ukwaja KN;Vollset SE;Weiderpass E;Libby EN;Fitzmaurice C
通讯作者: Fitzmaurice C
DOI: 10.1182/blood-2005-03-1301
发表时间: 2005-12-01
期刊: BLOOD
影响因子: 20.3
作者:
Bladé, J;Rosiñol, L;San Miguel, J
通讯作者: San Miguel, J